Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Hyperfine, Inc.NASDAQ: HYPR

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $725K fell 30.2% year over year, behind the +242.9% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 13.1% of revenue in FY2025, down 8.3 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.2% toward the trailing-twelve-month pace of +242.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$725K+440.4% QoQ
Last fiscal yearDec 2025
$1.78M+164.4% YoY
LTMMar 2026
$1.47M+242.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.2%——
1 year+164.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
1.78M USD
Year-over-year change
+164.4%
4-year CAGR
+16.1%

Accounts Receivables vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 accounts receivables of $1.47M is the 4th largest of the 7 companies compared; the peer median is $388K.
  • Its year-over-year change of +242.9% is the highest of 7, against a peer median of +131.3%.
  • Accounts receivables amounts to 9.6% of revenue for HYPR, versus a peer median of 5.6%.
HYPR Competitors Peer median
Accounts Receivables for HYPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$7.22M -27.6%+17.3%6.9%
RCELAVITA Medical, Inc.LTM Mar 2026$3.09M +162.7%—4.3%
LUNGPulmonx CorporationLTM Mar 2026$3M +188.4%—3.4%
HYPRHyperfine, Inc.LTM Mar 2026$1.47M +242.9%—9.6%
CNTBConnect Biopharma Holdings LimitedFY2025$776K +198.4%+512.8%1212.5%
VANIVivani Medical, Inc.LTM Mar 2026$522K -769.2%——
IMAImageneBio IncLTM Mar 2026$0 +100.0%——
Peer median (excluding HYPR) $388K+131.3%+265.1%5.6%

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Depreciation & Amortization726K1.02M1.05M1.01M1.09M
Deferred Income Tax00000
Stock-Based Compensation6.9M10.65M4.74M4.36M2.8M
Change in Working Capital8.97M(10.93M)(3.62M)(3.62M)4.41M
Accounts Receivables981K(1.55M)(1.57M)(2.77M)1.78M
Inventory(2.67M)(312K)(2.21M)562K(1.48M)
Accounts Payables1.44M(1.57M)533K382K2.43M
Other Working Capital9.22M(7.5M)(365K)(1.8M)1.68M
Other Non-Cash Items1.07M91K249K204K(677K)
Operating Cash Flow(47.18M)(72.34M)(41.81M)(38.77M)(27.95M)
Capital Expenditures(2.71M)(585K)(804K)(383K)(1.19M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(2.71M)(585K)(804K)(383K)(1.19M)
Debt Repayment(178K)0000
Common Stock Issued1.5M7K174K848K27.5M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities146.48M00171K0
Financing Cash Flow176.77M7K174K1.02M27.5M
Effect of Forex Changes00000
Net Change in Cash126.87M(72.92M)(42.44M)(38.13M)(1.63M)
Free Cash Flow(49.89M)(72.92M)(42.61M)(39.15M)(29.13M)

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.